BLA 761444 · Shanghai Henlius Biotech
Bilprevda
Denosumab-Nxxp · Injection · RANK Ligand Inhibitor
Last checked: Nov 20, 2026Latest source record: Oct 29, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Aug 29, 2025
Approved uses
2
Original approval plus efficacy supplements
Registered trials
287
81 Phase 3, 26 recruiting
FAERS reports
16,625
15,968 serious, 1,943 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 18, 2026.
Bilprevda is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 ) 1.1 Multiple Myeloma and Bone Metastasis from Solid Tumors Bilprevda is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. 1.2 Giant Cell Tumor of Bone Bilprevda is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [see Clinical Trials ( 14.2 )] . 1.3 Hypercalcemia of Malignancy Bilprevda is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
Mechanism: Denosumab products bind to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption, thereby modulating calcium release from bone. Increased osteoclast activity, stimulated by RANKL, is a mediator of bone pathology in solid tumors with osseous metastases.Similarly, giant cell tumors of bone consist of stromal cells expressing RANKL and osteoclast-like giant cells expressing RANK receptor, and signaling through the RANK receptor contributes to osteolysis and tumor growth. Denosumab products prevent...
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 29, 2025 Original approval · Efficacy LetterLabelMedication Guide
- Aug 29, 2025 Original approval LetterLabelReview
2 products under this application
- BILPREVDA · DENOSUMAB-NXXP 120MG/1.7ML(70MG/ML) · INJECTABLE, INJECTION · Prescription
- BILDYOS · DENOSUMAB-NXXP 60MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Denosumab" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate Denosumab in the Treatment of Postmenopausal OsteoporosisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00089791 · 7,808 participants · Start Aug 1, 2004 · Primary completion Jun 17, 2008
Drug: placebo; Denosumab · For: Osteoporosis
- Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With OsteoporosisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01575834 · 7,180 participants · Start Mar 15, 2012 · Primary completion Dec 14, 2015
Drug: Romosozumab; Placebo and 1 more · For: Postmenopausal Osteoporosis
Sites: Tucson, Arizona; Laguna Hills, California; Los Angeles, California · 218 sites in all
- Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of OsteoporosisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00523341 · 4,550 participants · Start Aug 7, 2007 · Primary completion Jul 19, 2015
Drug: Denosumab · For: Osteopenia; Osteoporosis
- Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)Pivotal-lookingTerminated
AmgenAmgen (AMGN)
NCT01077154 · 4,509 participants · Start Jun 2, 2010 · Primary completion Aug 31, 2017
Drug: Placebo; Denosumab · For: Breast Cancer
Sites: Birmingham, Alabama; Tucson, Arizona; Jonesboro, Arkansas · 459 sites in all
- Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor TherapyPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00556374 · 3,420 participants · Start Dec 18, 2006 · Primary completion Oct 7, 2014
Drug: Placebo; Denosumab and 2 more · For: Breast Cancer
Sites: Baden, Austria; Braunau am Inn, Austria; Dornbirn, Austria · 46 sites in all
- Study of the Key Techniques of Prevention and Treatment of Osteoporotic RefracturePivotal-lookingRecruiting
Peking Union Medical College HospitalAcademic, hospital or other
NCT05866029 · 2,478 participants (planned) · Start May 26, 2023 · Primary completion Sep 30, 2026
Drug: Denosumab; Teriparatide · For: Osteoporotic Fractures
Sites: Beijing, China; Changchun, China; Changsha, China · 58 sites in all
- A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00321464 · 2,049 participants · Start Apr 1, 2006 · Primary completion Jul 20, 2009
Drug: Denosumab; Zoledronic Acid · For: Bone Metastases
- Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate CancerPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00321620 · 1,904 participants · Start Apr 1, 2006 · Primary completion Oct 1, 2009
Drug: zoledronic acid; denosumab · For: Bone Metastases
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- osteonecrosis of jaw1,555
- diarrhoea1,177
- fatigue1,139
- nausea1,088
- malignant neoplasm progression1,072
- neutropenia981
- metastases to bone857
- off label use847
- anaemia758
- vomiting619
- dyspnoea609
- hypocalcaemia608
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 67 |
| 2011 | 136 |
| 2012 | 214 |
| 2013 | 358 |
| 2014 | 474 |
| 2015 | 662 |
| 2016 | 748 |
| 2017 | 636 |
| 2018 | 956 |
| 2019 | 1,013 |
| 2020 | 1,063 |
| 2021 | 1,495 |
| 2022 | 1,772 |
| 2023 | 1,781 |
| 2024 | 1,728 |
| 2025 | 1,749 |
| 2026 | 1,770 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
Händel MN, Cardoso I, von Bülow C, et al. · BMJ 2023 · Systematic Review, Network Meta-Analysis
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ayers C, Kansagara D, Lazur B, et al. · Ann Intern Med 2023 · Systematic Review, Network Meta-Analysis
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
Cosman F, Crittenden DB, Adachi JD, et al. · N Engl J Med 2016 · Multicenter Study, Randomized Controlled Trial
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Bone HG, Wagman RB, Brandi ML, et al. · Lancet Diabetes Endocrinol 2017 · Clinical Trial, Phase III, Multicenter Study
- Treatment of hypercalcaemia of malignancy in adults.
Mc Donald D, Drake MT, Crowley RK · Clin Med (Lond) 2023 · Meta-Analysis, Systematic Review
- Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Cummings SR, San Martin J, McClung MR, et al. · N Engl J Med 2009 · Multicenter Study, Randomized Controlled Trial
Sponsor: Shanghai Henlius Biotech · Also marketed as Bildyos
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.